|   | 
        
            
         | 
          | 
        
        
        
            | 
                
             | 
         
        
             | 
         
        
            
            
            
  
    
	  | 
   
  
    
        
          |   | 
          
              
                | 
                    ¾îÀǰíøīŸÇö󽺸¶  EUIGOCHUP CATAPLASMA[D-camphor , Gardenia fruit soft extract , Glycyrrhizinic acid , L-menthol , Methyl Salicylate , Phellodendr  
                    
                 | 
               
              
                | 
                     ÀϹÝÀǾàǰ | ºñ±Þ¿©  
                        
                    	
                    
                 | 
               
              
                | 
					  
                  
				  
                 | 
               
              
              
              
              
              |   |  
              
                
                    
                        | 
                      ¾Ë¸²:  | 
                      µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. | 
                     
                    | 
               
            
              
                
                   
                   
                   
                   
		   
                 | 
               
              
                | 
                  
                  
                 | 
               
              | 
            | 
         
       
       | 
   
    |  
  
    | 
      
     | 
     
  |  
                              
                                  | 
                                   | 
                               
            
            
                
            
            
              
            
                            
              
                                                     
            
            
   |  
  
    | 
      
     | 
   
   
     | 
   
    
   
    | 
       
        À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
        ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
        À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
        ·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
       
     | 
   
  
     | 
   
   
  
    
      
	
	  
	     |  
	    
	      
	        
            
                | Çã°¡Á¤º¸ | 
                         
	         
	       | 
	     
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
   
    û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå  »óÇÑ±Ý¾× | 
    
      
      
            ºñ±Þ¿©
          
        
      
    
    
      
     [»óº´ÄÚµåÁ¶È¸]
      
     [Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
     [¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
     | 
   
   
    | ºü¸¥Á¶È¸ | 
    
      
     |   
   
  
  
   
    | Á¦Ç°¼º»ó | 
    
      Ȳ°¥»öÀÇ Á¡Âø¼ºÀÇ °íü¸¦ ºÎÁ÷Æ÷ À§¿¡ µµÆ÷ÇÑ ¹æÇ⼺À» °¡Áø īŸÇö󽺸¶Á¦  
      
	    [Á¦ÇüÁ¤º¸ È®ÀÎ]
     |   
   
  
  
  
  
  
   
    | Æ÷À塤À¯Åë´ÜÀ§ | 
    6¸Å | 
   
  
  
  
  
  
  
  
  
  
  
  
  
   
    | º¸°ü¹æ¹ý | 
    ±â¹Ð¿ë±â, ½Ç¿Âº¸°ü(1-30¡É) | 
   
  
  
  
   
    | ¾à¸®ÀÛ¿ë | 
    
      
        [Á¶È¸]
     | 
      
  
  
  
  
   
    | È¿´ÉÈ¿°ú | 
    
    [ÀûÀÀÁõ º° °Ë»ö] 
     
    
     
	 
      ÁøÅë, ¼Ò¿°: ¿°ÁÂ, Ÿ¹Ú, ±ÙÀ°Åë, °üÀýÅë, °ñÀýÅë, ¿äÅë, °ßÅë, µ¿»ó
      
      
      
      
     | 
   
  
  
  
  
  
  
  
  
    
  
  
   
    | ¿ë¹ý¿ë·® | 
    
      * Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù. 
    
     
      
      
     [󹿾à¾î] 
      1ÀÏ 1-2ȸ ¾à¸éÀÇ ºñ´ÒÀ» ¶¼¾î¹ö¸®°í ³ª¼ ȯºÎ¿¡ ºÙÀδÙ.     
      	    
     | 
   
  
  
  
  
  
  
  
  
  
   
    | ±Ý±â | 
    
      - 30°³¿ù ÀÌÇÏÀÇ À¯¾Æ
 -  ´«ÁÖÀ§, Á¡¸· µî
 -  ½ÀÀ±, ¿Ì µî¿¡ ÀÇÇÑ ÇǺο°, »óóºÎÀ§
    
 
  | 
   
  
  
  
  
   
    | ½ÅÁßÅõ¿© | 
    - ¼Ò¾Æ¿¡ Àû¿ë½Ã °æ·ÃÀ» À¯¹ßÇÒ ¼ö ÀÖÀ¸¹Ç·Î ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
 - ´ÙÀ½ »ç¶÷Àº »ç¿ëÀü¿¡ ¾à»ç ¶Ç´Â ÀÇ»ç¿Í »óÀÇÇÑ´Ù. 
 ¾àÀ̳ª ÈÀåǰ µî¿¡ ÀÇÇÑ ¾Ë·¯Áö Áõ»ó(¹ßÁø, ¹ßÀû, °¡·Á¿òÁõ, ¿Ì µî¿¡ ÀÇÇÑ ÇǺο° µî)ÀÌ ³ªÅ¸³ ÀûÀÌ ÀÖ´Â »ç¶÷, ½ÀÀ±À̳ª Áø¹«¸§ÀÌ ½ÉÇÑ »ç¶÷, ÀÇ»çÀÇ Ä¡·á¸¦ ¹Þ°í ÀÖ´Â »ç¶÷. 
  | 
   
  
  
  
  
    
   
    | ÀϹÝÀû ÁÖÀÇ | 
    »ç¿ëÇÒ ¶§ ´ÙÀ½¿¡ ÁÖÀÇÇÑ´Ù. 
1) Á¤ÇØÁø ¿ë¹ý¡¤¿ë·®À» Àß ÁöŲ´Ù. 
2) ¼Ò¾Æ¿¡ »ç¿ëÇÒ °æ¿ì¿¡´Â º¸È£ÀÚÀÇ Áöµµ °¨µ¶ÇÏ¿¡ »ç¿ëÇÑ´Ù. 
3) º»Á¦´Â ¿Ü¿ëÀ¸·Î¸¸ »ç¿ëÇÏ°í ³»º¹ÇÏÁö ¾Ê´Â´Ù. 
-  »ç¿ëÁß ¶Ç´Â »ç¿ëÈÄ¿¡´Â ´ÙÀ½¿¡ ÁÖÀÇÇÑ´Ù.
 
1) º»Á¦ÀÇ »ç¿ëÀ¸·Î ÀÎÇØ ¹ßÁø, ¹ßÀû, °¡·Á¿ò µîÀÇ Áõ»óÀÌ ³ªÅ¸³ °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇÏ°í ¾à»ç ¶Ç´Â ÀÇ»ç¿Í »óÀÇÇÑ´Ù. 
2) ¼öÀϰ£ »ç¿ëÇÏ¿©µµ Áõ»óÀÌ °³¼±µÇÁö ¾ÊÀ» °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇÏ°í ¾à»ç ¶Ç´Â ÀÇ»ç¿Í »óÀÇÇÑ´Ù.
    | 
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  		
  
  
   
    | º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ | 
    -  ¾î¸°ÀÌÀÇ ¼ÕÀÌ ´êÁö ¾Ê´Â °÷¿¡ º¸°üÇÑ´Ù.
 -  Á÷»çÀϱ¤À» ÇÇÇÏ°í °¡´ÉÇÑ ÇÑ ¼´ÃÇÑ °÷¿¡ º¸°üÇÑ´Ù.
 -  ¿À¿ëÀ» ¸·°í ǰÁúÀÇ º¸Á¸À» À§ÇÏ¿© ´Ù¸¥ ¿ë±â¿¡ ¹Ù²Ù¾î ³ÖÁö ¾Ê´Â´Ù.
 
  | 
   
  	
  
  
  
  
  
  
   
    | Related FDA Approved Drug | 
    
       
     | 
      
  
  
      							
 
 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | Á¤º¸¿ä¾à | 
                 
	         
	       | 
	           	    
	     |  
	    | 
  
    µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
    
  
  
    
  
   |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | ÄÚµå ¹× ºÐ·ùÁ¤º¸ | 
                 
	         
	       | 
	           	    
	     |  
	    | 	 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | Á¦Ç°Á¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	     |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | º¹¾àÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	    | 
 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | ½É»çÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	     |  
	   
	   
	
	  
       |  
	    
	      
	        
            
                | ÇмúÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
    | DUR (ÀǾàǰ»ç¿ëÆò°¡) | 
    º´¿ë±Ý±â :
     
	 °í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
	 
	  [»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]										
	  ¿¬·É´ë±Ý±â :
      °í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
      
       [¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
       
       
        
        
     | 
   
  
   
    | µ¶¼ºÁ¤º¸ | 
    Camphor¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â 
Ethanol¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â 
L-Menthol¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â 
  Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do  | 
   
  
   
    | Mechanism of Action | 
    
       ethanol¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ The sedative effects of ethanol are mediated through binding to GABA receptors and glycine receptors (alpha 1 and alpha 2 subunits). In its role as an anti-infective, ethanol acts as an osmolyte or dehydrating agent that disrupts the osmotic balance across cell membranes. 
     | 
   
  
   
    | Pharmacology | 
     
       ethanol¿¡ ´ëÇÑ Pharmacology Á¤º¸ Alcohol produces injury to cells by dehydration and precipitation of the cytoplasm or protoplasm. This accounts for its bacteriocidal and antifungal action. When alcohol is injected in close proximity to nerve tissues, it produces neuritis and nerve degeneration (neurolysis). Ninety to 98% of ethanol that enters the body is completely oxidized. Ethanol is also used as a cosolvent to dissolve many insoluble drugs and to serve as a mild sedative in some medicinal formulations. 
     | 
   
  
   
    | Half-life | 
    
       ethanol¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available 
     | 
   
  
   
    | Absorption | 
    
       ethanol¿¡ ´ëÇÑ Absorption Á¤º¸ Rapidly absorbed. 
     | 
   
  
   
    | Pharmacokinetics | 
    
       Methyl SalicylateÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á 
 
	- Èí¼ö : 
 
		
	-    À§Àå°üÀ¸·ÎºÎÅÍ Àß Èí¼öµÈ´Ù.
 
	 -    ¹þ°ÜÁø ÇǺθ¦ ÅëÇØ¼µµ Èí¼öµÉ ¼ö ÀÖ´Ù.
 
 		  
  
 L-mentholÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á 
- ¼Ò½Ç : Èí¼öµÈ ¾à¹°Àº glucuronide Æ÷ÇÕü·Î¼ ¼Òº¯ ¹× ´ãÁóÀ» ÅëÇØ ¹è¼³µÈ´Ù.
  
     | 
   
  
   
    | Biotransformation | 
    
       ethanol¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic. Metabolized by cytochrome P450 enzyme CYP2E1. 
     | 
   
  
   
    | Toxicity | 
    
       ethanol¿¡ ´ëÇÑ Toxicity Á¤º¸ Oral, rat LD50: 5628 mg/kg. Symptoms and effects of overdose include nausea, vomiting, CNS depression, acute respiratory failure or death and with chronic use, severe health problems, such as liver and brain damage. 
     | 
   
  
   
    | Drug Interactions | 
    
       ethanol¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available 
     | 
   
  
   
    CYP450  Drug Interaction | 
    
      [CYP450 TableÁ÷Á¢Á¶È¸] ethanol¿¡ ´ëÇÑ P450 table
  SUBSTRATES 
CYP 2E1 
acetaminophen 
chlorzoxazone 
**ethanol** 
 INHIBITORS 
CYP 2E1 
disulfiram 
 INDUCERS 
CYP 2E1 
**ethanol** 
isoniazid 
  SUBSTRATES 
CYP 2E1 
acetaminophen 
chlorzoxazone 
**ethanol** 
 INHIBITORS 
CYP 2E1 
disulfiram 
 INDUCERS 
CYP 2E1 
**ethanol** 
isoniazid 
     | 
   
  
   
    | Drug Target | 
    
      
      [Drug Target]
     | 
   
  
   
    | Description | 
    
       ethanol¿¡ ´ëÇÑ Description Á¤º¸ A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in alcoholic beverages. [PubChem] 
     | 
   
  
   
    | Dosage Form | 
    
       ethanol¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Aerosol	TopicalGel	TopicalLiquid	IntramuscularLiquid	IntravenousLiquid	OralLiquid	TopicalLotion	TopicalSolution	TopicalSolution / drops	OralSpray	Topical 
     | 
   
  
   
    | Drug Category | 
    
       ethanol¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Infective Agents, LocalCentral Nervous System DepressantsDisinfectantsSolvents 
     | 
   
  
   
    | Smiles String Canonical | 
    
       ethanol¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCO 
     | 
   
  
   
    | Smiles String Isomeric | 
    
       ethanol¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CCO 
     | 
   
  
   
    | InChI Identifier | 
    
       ethanol¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ Not Available 
     | 
   
  
   
    | Chemical IUPAC Name | 
    
       ethanol¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ ethanol 
     | 
   
  
   
    | Drug-Induced Toxicity Related Proteins | 
    
      ETHANOL ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Proenkephalin  Drug:ethanol Toxicity:ethanol narcosis.  [¹Ù·Î°¡±â] Replated Protein:Insulin receptor substrate 1 Drug:Ethanol  Toxicity:impair liver regeneration, inhibit DNA synthesis, and mute cellular responses to growth factor stimulation.  [¹Ù·Î°¡±â] Replated Protein:Phosphatidylinositol-4-phosphate 3-kinase Drug:Ethanol  Toxicity:impair liver regeneration, inhibit DNA synthesis, and mute cellular responses to growth factor stimulation.  [¹Ù·Î°¡±â] Replated Protein:Insulin receptor substrate 2 Drug:Ethanol  Toxicity:impair liver regeneration, inhibit DNA synthesis, and mute cellular responses to growth factor stimulation.  [¹Ù·Î°¡±â] Replated Protein:Mitogen-activated protein kinase(Erk2) Drug:Ethanol  Toxicity:impair liver regeneration, inhibit DNA synthesis, and mute cellular responses to growth factor stimulation.  [¹Ù·Î°¡±â] Replated Protein:Mitogen-activated protein kinase  Drug:Ethanol  Toxicity:impair liver regeneration, inhibit DNA synthesis, and mute cellular responses to growth factor stimulation.  [¹Ù·Î°¡±â] 
     | 
   
    
  |  
	   
	   
	
	  
       |  
	    
	      
	        
            
                | »ç¿ëÀÚÄÁÅÙÃ÷ | 
                             
	         
	       | 
	           	  
       |  
	     |  
	   
	     	
 
  | 
   
   
     | 
   
  
    
      
        
          
            
              - 
                ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2022-10-24
              
 
              - 
                
                º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
                
              
     
             
         |                 
       
     |       
          
                
                    
                       ¾Ë¸² | 
                       
                      »ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.  | 
                    
                    | 
               
      
      
                
                    
                       °æ°í | 
                     
                      µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù. 
                          Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â 
                          Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
                            ¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
                          ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
 | 
                    
                    | 
               
  
 
  
    ¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é 
    ¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
   
  
 
  º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
 
 |  
             
             | 
         
         
         | 
         |